Histology
Adenocarcinoma
CI-CAN-00000403Explore in graph →
2,751 active trials43 approved drugs423 evidence items
Loading cancer entity…
Loading cancer entity…
Histology
CI-CAN-00000403Explore in graph →
Clinical trials
9,697 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (1,318)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT00077441 | Bortezomib in Treating Patients With Hepatocellular Carcinoma (Liver Cancer) | completed | Phase 2 | 55 | National Cancer Institute (NCI)NIH | 1 | Jun 4, 2013 | clinicaltrials |
| NCT00084604 | Irinotecan, Cisplatin, and Bevacizumab in Treating Patients With Unresectable or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma | completed | Phase 2 | 47 | National Cancer Institute (NCI)NIH | 1 | Jun 4, 2013 | clinicaltrials |
| NCT00118183 | Docetaxel With Either Cetuximab or Bortezomib as First-Line Therapy in Treating Patients With Stage III or Stage IV Non-Small Cell Lung Cancer | completed | Phase 2 | 62 | National Cancer Institute (NCI)NIH | 1 | Jun 4, 2013 | clinicaltrials |
| NCT00397787 | Sunitinib in Treating Patients With Metastatic Pancreatic Cancer That Progressed After First-Line Therapy With Gemcitabine | completed | Phase 2 | 64 | National Cancer Institute (NCI)NIH | 1 | Jun 4, 2013 | clinicaltrials |
| NCT01858207 | Combine TACE and RFA Versus RFA Monotherapy in Unilobar HCC of 3.1 to 7 cm Patient | unknown | Phase 2 | 60 | Shi-Ming LinOTHER | 1 | May 23, 2013 | clinicaltrials |
| NCT00707889 | Phase 2 Study of ABT-869 in Combination With mFOLFOX6 Versus Bevacizumab in Combination With mFOLFOX6 to Treat Advanced Colorectal Cancer | completed | Phase 2 | 159 | AbbVie (prior sponsor, Abbott)INDUSTRY | 14 | May 15, 2013 | clinicaltrials |
| NCT00425035 | Safety and Efficacy Study of ABX-EGF in Patients With Renal Cancer, Part 2 | completed | Phase 2 | 115 | AmgenINDUSTRY | 0 | May 13, 2013 | clinicaltrials |
| NCT00242502 | Efficacy and Safety Study of Bevacizumab and Erlotinib to Treat Primary Liver Cancer That Cannot be Removed By Surgery | completed | Phase 2 | 62 | M.D. Anderson Cancer CenterOTHER | 1 | May 6, 2013 | clinicaltrials |
| NCT00491075 | Pemetrexed Plus Gemcitabine in Renal Cell Cancer | terminated | Phase 2 | 16 | M.D. Anderson Cancer CenterOTHER | 1 | Apr 24, 2013 | clinicaltrials |
| NCT01821482 | A Study of DC-CIK to Treat Hepatocellular Carcinoma | unknown | Phase 2 | 100 | Guangxi Medical UniversityOTHER | 1 | Apr 12, 2013 | clinicaltrials |
| NCT01616186 | Everolimus/Sorafenib or Sunitinib in Patients With Metastatic Renal Cell Carcinoma (RCC) | withdrawn | Phase 2 | 0 | Andrea HarzstarkOTHER | 0 | Apr 8, 2013 | clinicaltrials |
| NCT00182702 | Ixabepilone in Treating Patients With Metastatic, Recurrent, or Unresectable Kidney Cancer | completed | Phase 2 | 37 | National Cancer Institute (NCI)NIH | 1 | Mar 25, 2013 | clinicaltrials |
| NCT00494091 | Study Evaluating The Safety, Efficacy & Pharmacokinetics Of Temsirolimus(CCI-779) In Subjects With Advanced Renal Cell Carcinoma | completed | Phase 2 | 82 | PfizerINDUSTRY | 3 | Mar 21, 2013 | clinicaltrials |
| NCT00405873 | Study to Evaluate Tumour Response in Cancer Patients With Advanced Hepatocellular Carcinoma (Liver Cancer) With AMT2003 | terminated | Phase 2 | 73 | Auron Healthcare GmbHINDUSTRY | 1 | Mar 20, 2013 | clinicaltrials |
| NCT00490698 | Zoledronate With Atorvastatin in Renal Cell Carcinoma | completed | Phase 2 | 11 | M.D. Anderson Cancer CenterOTHER | 1 | Mar 18, 2013 | clinicaltrials |
| NCT01811277 | SOX Sequential S-1 in Advanced Biliary Tract Carcinoma（BTC）and Pancreatic Cancer | unknown | Phase 2 | 40 | Peking UniversityOTHER | 1 | Mar 15, 2013 | clinicaltrials |
| NCT00272649 | Study Testing the Biologic Activity and Safety of an Immunotherapeutic in Patients With Newly Diagnosed Stage IV Kidney Cancer | completed | Phase 1 / Phase 2 | 22 | Argos TherapeuticsINDUSTRY | 2 | Mar 14, 2013 | clinicaltrials |
| NCT00429026 | Conditioning Regimen in Nonmyeloablative Allogeneic Hematopoietic Stem Cell Transplantation | terminated | Phase 2 | 40 | M.D. Anderson Cancer CenterOTHER | 1 | Mar 4, 2013 | clinicaltrials |
| NCT00029003 | Gefitinib in Treating Patients With Stage IIIB or Stage IV Non-Small Cell Lung Cancer | completed | Phase 2 | 90 | National Cancer Institute (NCI)NIH | 1 | Feb 28, 2013 | clinicaltrials |
| NCT00060307 | Erlotinib in Treating Patients With Locally Advanced or Metastatic Papillary Renal Cell Cancer | completed | Phase 2 | 40 | National Cancer Institute (NCI)NIH | 1 | Feb 28, 2013 | clinicaltrials |
| NCT00087412 | S0341: Erlotinib in Treating Patients With Advanced Primary Non-Small Cell Lung Cancer | completed | Phase 2 | 65 | National Cancer Institute (NCI)NIH | 1 | Feb 28, 2013 | clinicaltrials |
| NCT00101114 | Sorafenib and Interferon Alfa in Treating Patients With Metastatic or Unresectable Kidney Cancer | completed | Phase 2 | 55 | National Cancer Institute (NCI)NIH | 1 | Feb 28, 2013 | clinicaltrials |
| NCT00126607 | Trastuzumab in Treating Patients With Metastatic or Recurrent Salivary Gland Cancer | terminated | Phase 2 | 35 | National Cancer Institute (NCI)NIH | 1 | Feb 28, 2013 | clinicaltrials |
| NCT00988741 | Trial of ARQ 197 in Patients With Unresectable Hepatocellular Carcinoma (HCC) Who Have Failed One Prior Systemic Therapy | completed | Phase 2 | 107 | ArQule, Inc., a subsidiary of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc. (Rahway, NJ USA)INDUSTRY | 5 | Feb 28, 2013 | clinicaltrials |
| NCT00021060 | Combination Chemotherapy With or Without Bevacizumab in Treating Patients With Advanced, Metastatic, or Recurrent Non-Small Cell Lung Cancer | completed | Phase 2 / Phase 3 | 842 | National Cancer Institute (NCI)NIH | 1 | Feb 27, 2013 | clinicaltrials |
| NCT00071994 | Gefitinib in Treating Patients With Advanced Unresectable Hepatocellular Carcinoma (Liver Cancer) | completed | Phase 2 | 59 | National Cancer Institute (NCI)NIH | 1 | Feb 27, 2013 | clinicaltrials |
| NCT00087984 | RNA-Loaded Dendritic Cell Cancer Vaccine | completed | Phase 1 / Phase 2 | 26 | Argos TherapeuticsINDUSTRY | 2 | Feb 18, 2013 | clinicaltrials |
| NCT01394497 | Use of N-Acetylcysteine During Liver Procurement | completed | Phase 2 | 140 | Azienda Ospedaliera di PadovaOTHER | 1 | Feb 18, 2013 | clinicaltrials |
| NCT00619268 | Combination of Temsirolimus and Bevacizumab in Patient With Metastatic Renal Cell Carcinoma(TORAVA) | completed | Phase 2 | 160 | Centre Leon BerardOTHER | 1 | Feb 15, 2013 | clinicaltrials |
| NCT00106353 | Study Evaluating Biomarkers In Relapsed/Refractory Pediatric Solid Tumors | completed | Phase 1 / Phase 2 | 71 | PfizerINDUSTRY | 7 | Feb 8, 2013 | clinicaltrials |
| NCT00557609 | Phase 2 Study in Patients With MiT Tumors | completed | Phase 2 | 47 | ArQule, Inc., a subsidiary of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc. (Rahway, NJ USA)INDUSTRY | 3 | Feb 8, 2013 | clinicaltrials |
| NCT01523015 | Efficacy and Safety Study of the Combined Modality Therapy in Adenocarcinoma of the Esophago-gastric Junction | unknown | Phase 2 / Phase 3 | 100 | Medical University of LublinOTHER | 1 | Feb 5, 2013 | clinicaltrials |
| NCT00251316 | Effect of Lithium Carbonate on Low-Dose Radioiodine Therapy in Early Thyroid Cancer | completed | Phase 2 | 34 | National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)NIH | 1 | Feb 4, 2013 | clinicaltrials |
| NCT00002796 | Phase I-II Study of Fluorouracil in Combination With Phenylbutyrate in Advanced Colorectal Cancer | terminated | Phase 1 / Phase 2 | 46 | National Cancer Institute (NCI)NIH | 1 | Feb 1, 2013 | clinicaltrials |
| NCT00040755 | BMS-275291 in Treating Patients With Prostate Cancer That Has Not Responded to Hormone Therapy | completed | Phase 2 | 68 | National Cancer Institute (NCI)NIH | 1 | Feb 1, 2013 | clinicaltrials |
| NCT00193258 | Bevacizumab, Erlotinib, and Imatinib in the Treatment of Advanced Renal Cell Carcinoma | completed | Phase 1 / Phase 2 | 94 | SCRI Development Innovations, LLCOTHER | 0 | Jan 31, 2013 | clinicaltrials |
| NCT00096499 | SB-715992 in Treating Patients With Metastatic Prostate Cancer That Did Not Respond to Docetaxel or Paclitaxel | completed | Phase 2 | 40 | National Cancer Institute (NCI)NIH | 1 | Jan 25, 2013 | clinicaltrials |
| NCT00005039 | Vaccine Therapy in Treating Patients With Advanced Adenocarcinoma of the Prostate (Prostate Cancer) | terminated | Phase 2 | 86 | National Cancer Institute (NCI)NIH | 1 | Jan 24, 2013 | clinicaltrials |
| NCT00025467 | Thalidomide in Treating Patients With Recurrent or Persistent Endometrial Cancer | completed | Phase 2 | 60 | National Cancer Institute (NCI)NIH | 1 | Jan 24, 2013 | clinicaltrials |
| NCT00028834 | Bevacizumab and Gemcitabine in Treating Patients With Advanced Pancreatic Cancer | completed | Phase 2 | 50 | National Cancer Institute (NCI)NIH | 1 | Jan 24, 2013 | clinicaltrials |
| NCT00032188 | Interleukin-2 and Bryostatin 1 in Treating Patients With Advanced Kidney Cancer | completed | Phase 2 | 65 | National Cancer Institute (NCI)NIH | 1 | Jan 24, 2013 | clinicaltrials |
| NCT00005818 | SU5416 and Irinotecan in Treating Patients With Advanced Colorectal Cancer | completed | Phase 1 / Phase 2 | 68 | National Cancer Institute (NCI)NIH | 1 | Jan 23, 2013 | clinicaltrials |
| NCT00009919 | SU5416 in Treating Patients With Metastatic Kidney Cancer That Has Not Responded to Previous Treatment | terminated | Phase 2 | 50 | National Cancer Institute (NCI)NIH | 1 | Jan 23, 2013 | clinicaltrials |
| NCT00047333 | Erlotinib in Treating Patients With Liver Cancer That Cannot be Surgically Removed | terminated | Phase 2 | 80 | National Cancer Institute (NCI)NIH | 1 | Jan 23, 2013 | clinicaltrials |
| NCT00061958 | Arsenic Trioxide in Treating Patients With Advanced Cancer of the Esophagus or Gastroesophageal Junction | terminated | Phase 2 | 50 | National Cancer Institute (NCI)NIH | 1 | Jan 23, 2013 | clinicaltrials |
| NCT00109811 | Vaccine Therapy in Treating Patients With Recurrent Prostate Cancer | completed | Phase 2 | 32 | National Cancer Institute (NCI)NIH | 1 | Jan 23, 2013 | clinicaltrials |
| NCT01619696 | Prospective Pilot Study of Multimodal Radiological Evaluation Feasibility During Chemoradiotherapy of Rectal Adenocarcinomas | terminated | Phase 2 | 3 | University Hospital, ToulouseOTHER | 1 | Jan 23, 2013 | clinicaltrials |
| NCT00075647 | CCI-779 in Treating Patients With Locally Advanced or Metastatic Pancreatic Cancer | completed | Phase 2 | 40 | National Cancer Institute (NCI)NIH | 1 | Jan 17, 2013 | clinicaltrials |
| NCT00103324 | S0413 Lapatinib in Treating Patients With Locally Advanced or Metastatic Stomach Cancer | completed | Phase 2 | 40 | National Cancer Institute (NCI)NIH | 1 | Jan 17, 2013 | clinicaltrials |
| NCT00006094 | Oxaliplatin, Fluorouracil, and External-Beam Radiation Therapy Followed by Surgery in Treating Patients With Locally Advanced Cancer of the Rectum | completed | Phase 1 / Phase 2 | 24 | National Cancer Institute (NCI)NIH | 1 | Jan 16, 2013 | clinicaltrials |
Data updated 23 days agoSource updated Jun 4, 2013source: clinicaltrials